Personalis, Inc.
HealthcareNASDAQ:PSNL · NASDAQ Global Market
+$0.17 today
Vol 1.94M · Avg 2.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-31.1%
avg -25.4%
ROIC
-29.9%
avg -128.9%
ROA
-24.3%
avg -34.3%
Analysis
ROA is currently the strongest return metric at -24.3% versus its period average of -34.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher Hall | CEO & Director | $868,200.00 | — | 57 | $300,000.00 | 0.34% |
Aaron L. Tachibana | Chief Financial Officer & Chief Operating Officer | $679,900.00 | — | 65 | $28,832.00 | 0.03% |
Richard Chen | Executive Vice President of R&D and Chief Medical Officer | $660,750.00 | — | 55 | $281,250.00 | 0.32% |
Stephen Moore | Senior Vice President, Chief Legal Officer & Corporate Secretary | $597,975.00 | — | 54 | $168,750.00 | 0.19% |
Stephane Mouradian | Senior Vice President of Business Development | — | — | — | — | — |
Christian Haudenschild | Senior Vice President of Genomic Science | — | — | — | — | — |
Michael Snyder | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | — | $168,750.00 | 0.19% |
Russ Altman | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | — | — | — |
Ashish Kheterpal | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Euan A. Ashley DPHIL FRCP | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | 55 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$2.74M
Sells
8
$3.22M
Net Sentiment
$477,859.50
Net selling
Most Active
Tempus AI, Inc.
12 transactions
1–10 of 20
Analysis
Insiders reported 12 buys worth $2.74M and 8 sells worth $3.22M over the last 12 months. That adds up to net selling of $477,859.50. Tempus AI, Inc. was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +31.3% | +11.5% (9yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +31.3% over three years. Forward estimates point to Revenue at +11.5% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Castle Biosciences, Inc.
NASDAQ:CSTL
$627.83M
Evolent Health, Inc.
NYSE:EVH
$539.91M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
Who manages PSNL?
Personalis, Inc. (PSNL) lists 10 active executives. The top listed executive is Stephane Mouradian, Senior Vice President of Business Development.
Are PSNL insiders buying or selling?
Recent insider activity shows net buying of $22.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.